GYRE
Price
$8.41
Change
+$0.44 (+5.52%)
Updated
Jun 6 closing price
Capitalization
717.17M
72 days until earnings call
SPHDF
Price
$14.75
Change
-$1.15 (-7.23%)
Updated
May 28 closing price
Capitalization
205.41M
Interact to see
Advertisement

GYRE vs SPHDF

Header iconGYRE vs SPHDF Comparison
Open Charts GYRE vs SPHDFBanner chart's image
Gyre Therapeutics
Price$8.41
Change+$0.44 (+5.52%)
Volume$158.31K
Capitalization717.17M
Santhera Pharmaceuticals Holdings
Price$14.75
Change-$1.15 (-7.23%)
Volume$285
Capitalization205.41M
GYRE vs SPHDF Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. SPHDF commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a StrongBuy and SPHDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (GYRE: $9.44 vs. SPHDF: $14.75)
Brand notoriety: GYRE and SPHDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 198% vs. SPHDF: 178%
Market capitalization -- GYRE: $717.17M vs. SPHDF: $205.41M
GYRE [@Biotechnology] is valued at $717.17M. SPHDF’s [@Biotechnology] market capitalization is $205.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 2 FA rating(s) are green whileSPHDF’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 2 green, 3 red.
  • SPHDF’s FA Score: 1 green, 4 red.
According to our system of comparison, both GYRE and SPHDF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 4 TA indicator(s) are bullish.

  • GYRE’s TA Score: 4 bullish, 6 bearish.

Price Growth

GYRE (@Biotechnology) experienced а -8.97% price change this week, while SPHDF (@Biotechnology) price change was -15.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($717M) has a higher market cap than SPHDF($205M). GYRE has higher P/E ratio than SPHDF: GYRE (397.00) vs SPHDF (2.52). SPHDF YTD gains are higher at: 56.582 vs. GYRE (-21.983).
GYRESPHDFGYRE / SPHDF
Capitalization717M205M350%
EBITDA17.8MN/A-
Gain YTD-21.98356.582-39%
P/E Ratio397.002.5215,758%
Revenue106MN/A-
Total Cash26.7MN/A-
Total Debt1.6MN/A-
FUNDAMENTALS RATINGS
GYRE vs SPHDF: Fundamental Ratings
GYRE
SPHDF
OUTLOOK RATING
1..100
995
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
19100
PRICE GROWTH RATING
1..100
5839
P/E GROWTH RATING
1..100
412
SEASONALITY SCORE
1..100
2732

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHDF's Valuation (62) in the null industry is somewhat better than the same rating for GYRE (95). This means that SPHDF’s stock grew somewhat faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (83) in the null industry is in the same range as SPHDF (100). This means that GYRE’s stock grew similarly to SPHDF’s over the last 12 months.

GYRE's SMR Rating (19) in the null industry is significantly better than the same rating for SPHDF (100). This means that GYRE’s stock grew significantly faster than SPHDF’s over the last 12 months.

SPHDF's Price Growth Rating (39) in the null industry is in the same range as GYRE (58). This means that SPHDF’s stock grew similarly to GYRE’s over the last 12 months.

GYRE's P/E Growth Rating (4) in the null industry is in the same range as SPHDF (12). This means that GYRE’s stock grew similarly to SPHDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYRE
RSI
ODDS (%)
Bearish Trend 12 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
83%
Momentum
ODDS (%)
Bearish Trend 12 days ago
83%
MACD
ODDS (%)
Bearish Trend 12 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
82%
Advances
ODDS (%)
Bullish Trend 24 days ago
82%
Declines
ODDS (%)
Bearish Trend about 1 month ago
83%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
85%
Aroon
ODDS (%)
Bullish Trend 12 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been closely correlated with SPHDF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GYRE jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-7.27%
SPHDF - GYRE
82%
Closely correlated
-7.23%
SPRC - GYRE
38%
Loosely correlated
+2.32%
AURA - GYRE
38%
Loosely correlated
+0.17%
BEAM - GYRE
37%
Loosely correlated
-0.88%
PYXS - GYRE
37%
Loosely correlated
-3.23%
More

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been closely correlated with GYRE. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPHDF jumps, then GYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
-7.23%
GYRE - SPHDF
82%
Closely correlated
-7.27%
HRMY - SPHDF
37%
Loosely correlated
-0.21%
SPRC - SPHDF
34%
Loosely correlated
+2.32%
INM - SPHDF
33%
Poorly correlated
-5.40%
RVMD - SPHDF
33%
Poorly correlated
+2.04%
More